The pill offers an alternative to injections, which some people find difficult or unpleasant.<\/p>\n<\/h3>\n
By I. Edwards HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, Aug. 27, 2025 (HealthDay News) \u2014 Eli Lilly<\/a> says its new once-daily pill, orforglipron<\/a>, helped people lose significant weight and lower blood sugar in a late-stage clinical trial.<\/p>\n The company plans to seek global regulatory approval later this year.<\/p>\n The study included people with overweight, obesity and type 2 diabetes<\/a>. Participants who took the highest dose of the drug (36 milligrams) lost an average of 22.9 pounds \u2014 about 10.5% of their body weight \u2014 after 72 weeks. The pill also lowered A1C levels \u2014 a measure of blood sugar control \u2014 by 1.8% on average, CNN <\/em>reported.<\/p>\n Those results, which have not been peer-reviewed, were lower than weight loss figures announced<\/a> earlier this month, when the company reported that the highest dose helped patients shed an average 27.3 pounds, or 12.4% of their body weight.<\/p>\n Unlike Rybelsus<\/a>, the only semaglutide pill currently available, orforglipron doesn\u2019t require strict fasting or limited water intake.<\/p>\n The pill offers an alternative to injections, which some people find difficult or unpleasant.<\/p>\n Eli Lilly says side effects were mostly mild to moderate, with upset stomach being the most common.<\/p>\n If approved, orforglipron could offer millions of people with obesity or type 2 diabetes another treatment option. The company is also testing whether the pill may help with other conditions, including high blood pressure and sleep apnea.<\/p>\n With earlier promising trial results, the company has been mass-producing the pills for months.<\/p>\n \u201cThat way, we\u2019ll have adequate supply to meet demand,\u201d Dr. Dan Skovronsky<\/a>, Lilly\u2019s chief scientific officer, told CNN.<\/em><\/p>\n More information<\/strong><\/p>\n Cleveland Clinic has more on GLP-1 agonists<\/a>.<\/p>\n